Agenus to Report First Quarter 2015 Financial Results on April 23, 2015; Conference Call to Follow
April 20 2015 - 7:49AM
Business Wire
Agenus Inc. (NASDAQ: AGEN) will release its first quarter 2015
financial results before the market opens on Thursday, April 23,
2015. Agenus executives will host a conference call at 11 a.m.
Eastern Time the same day.
To access the live call, dial 866-233-4585 (U.S.) or
416-640-5946 (international). The call will also be webcast and
will be accessible from the company’s website at
www.agenusbio.com/webcast/. A replay will be available on the
company’s website approximately two hours after the call and will
remain available for 60 days. The replay number is 866-245-6755
(U.S.) or 416-915-1035 (international), and the access code is
601129.
About Agenus
Agenus is an immunology company developing a series of
immuno-oncology CPMs, heat shock protein peptide-based vaccines and
immune adjuvants. These programs are supported by three separate
technology platforms. Agenus’ checkpoint modulator programs target
GITR, OX40, CTLA-4, LAG-3, TIM-3 and PD-1. The company’s
proprietary discovery engine Retrocyte DisplayTM is used to
generate fully human and humanized therapeutic antibody drug
candidates. The Retrocyte Display platform uses a high-throughput
approach incorporating IgG format human antibody libraries
expressed in mammalian B-lineage cells. Agenus recently acquired a
powerful yeast antibody display platform termed SECANT, developed
by Celexion. SECANT allows rapid generation of soluble, full-length
human antibodies. It and 4-Ab's mammalian antibody display platform
have complementary strengths and further bolster Agenus' abilities
to generate and optimize fully human monoclonal antibodies. Agenus’
heat shock protein peptide-based vaccines have completed Phase 2
studies in newly diagnosed glioblastoma multiforme, and in the
treatment of herpes simplex viral infection; the heat shock
protein-based vaccine platform can generate personalized as well as
off the shelf products. The company’s QS-21 Stimulon® adjuvant
platform is extensively partnered with GlaxoSmithKline and Janssen
Sciences Ireland UC and includes several candidates in Phase 2
trials, as well as shingles and malaria vaccines which have
successfully completed Phase 3 clinical trials. For more
information, please visit www.agenusbio.com, or connect with the
company on Facebook, LinkedIn, Twitter and Google+.
Forward-Looking Statement
This press release contains forward-looking statements,
including statements regarding the Company’s anticipated timing for
releasing its first quarter 2015 financial results. These
forward-looking statements are subject to risks and uncertainties
that could cause actual results to differ materially. These risks
and uncertainties include, among others, the factors described
under the Risk Factors section of our most recent Quarterly Report
on Form 10-Q or annual report on Form 10-K filed with the
Securities and Exchange Commission. Agenus cautions investors not
to place considerable reliance on the forward-looking statements
contained in this release. These statements speak only as of the
date of this press release, and Agenus undertakes no obligation to
update or revise the statements, other than to the extent required
by law. All forward-looking statements are expressly qualified in
their entirety by this cautionary statement.
Media:BMC CommunicationsBrad Miles,
646-513-3125bmiles@bmccommunications.comorInvestors:Argot
PartnersAndrea Rabney/Jamie Maarten,
212-600-1902andrea@argotpartners.comjamie@argotpartners.com
Agenus (NASDAQ:AGEN)
Historical Stock Chart
From Jun 2024 to Jul 2024
Agenus (NASDAQ:AGEN)
Historical Stock Chart
From Jul 2023 to Jul 2024